## **Amendments to the Claims**

Claims 1-3 (cancelled)

Claim 4 (previously amended): A method as claimed in claim 38, wherein vascular collateralization of the embolized vasculature is absent or sufficiently delayed such that said composition is therapeutically effective.

Claim 5 (currently amended): A method as claimed in claim 38, wherein said water-insoluble particles comprisenon-polymeric particulate matrix comprises an insoluble phosphate salt of the formula

 $M_{10}(PO_4)_6A_z$ 

wherein

M = Ba, Ca, Cd, Mg, Pb or Sr

 $A = OH^{-}, C1^{-}, F^{-} \text{ or } CO_{2}^{-2}$ 

Z = 2 if A is univalent, 1 if A is divalent.

Claim 6 (previously amended): A method as claimed in claim 5, wherein said insoluble phosphate salt is hyroxyapatite,  $Ca_{10}$  (PO<sub>4</sub>)<sub>6</sub>OH<sub>2</sub>.

Claim 7 (cancelled)

Claims 8-37 (withdrawn)



Claim 38 (currently amended): A method of embolus therapy comprising the steps of: introducing a composition into the vasculature of a human or non-human animal subject an embolus generating composition comprising particles of a size or formulation selected to generate emboli at a target site within said subject, wherein said composition includes solid water insoluble particles 1–5010-20 micrometers in size consisting essentially of a non-radioactive diagnostically effective compound or solution thereof encapsulated in a non-polymeric particulate matrix selected from the group consisting of insoluble metal oxides, insoluble metal salts, inert metals, glass, ceramic particles and porous particles, or vesicles encapsulating a non-radioactive diagnostically effective compound, or a solution thereof, and wherein said composition further comprises an iodinated contrast agent, MR active agent, or ultrasound contrast agent imageable marker to identify the extent of embolization; and detecting the embolus location by a diagnostic imaging technique.

Claims 39-40 (cancelled)